IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced two new distribution agreements. Inter V Medical of Montreal, Quebec, Canada will have exclusive rights to sell Cesium-131 Brachytherapy seeds in Canada. GE Subsidary, Oncura will distribute the I-125 brachytherapy seed, OncoSeed™.
In a press release, Dwight Babcock, Chairman and CEO stated, “By adding I-125 seeds to our prostate product offering we can now be a full service provider to our customers. OncoSeed brings with it a substantial and well documented track record of efficacy. While we believe that Cesium-131 adds an important new dimension to brachytherapy for a variety of anatomic sites including prostate, we see strategic value in supporting our customers that have not yet converted all their practice to Cesium-131.”
Related external links (will open a new window):
IsoRay – Richland, Wash. – December 3, 2009
IsoRay – Richland, Wash. – November 18, 2009
Related WTC links:
– end of post –